Literature DB >> 28438772

Severe vincristine-induced polyneuropathy in a teenager with anaplastic medulloblastoma and undiagnosed Charcot-Marie-Tooth disease.

Yasmin Aghajan1, Janet M Yoon2, John Ross Crawford3.   

Abstract

Severe neuropathy is a known adverse effect of vincristine in patients with Charcot-Marie-Tooth disease (CMT). We present the case of a 16-year-old girl with anaplastic medulloblastoma treated with gross total resection and high-dose craniospinal radiation with adjuvant vincristine chemotherapy who developed acute-onset severe quadriplegia and vocal cord paralysis. Vincristine and radiation therapy were discontinued. Although her neuropathy slowly improved over several weeks, she developed metastatic extraneural medulloblastoma and died 5 months after diagnosis. Subsequent genetic testing revealed previously asymptomatic and undiagnosed CMT1A. Our case highlights the importance of early recognition of acute vincristine neurotoxicity that should raise suspicion of an underlying hereditary neuropathy. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  CNS cancer; Chemotherapy; Neurology; Neuromuscular disease; Neurooncology

Mesh:

Substances:

Year:  2017        PMID: 28438772      PMCID: PMC5534873          DOI: 10.1136/bcr-2016-218981

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

1.  Treatment-induced remission of medulloblastoma using a chemotherapeutic regimen devoid of vincristine in a child with Charcot-Marie-Tooth disease.

Authors:  J D Bernstock; J L Cohen; S Singh; C W Schlappi; J B Fiveash; J M Johnston; P Fequiere; B A Orr; R Li; G K Friedman
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

2.  Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1).

Authors:  Patrick P Hess; Monica S Ventura Ferreira; Benjamin Rolles; Martin Kirschner; Florian Holtbernd; Mareike Tometten; Tim H Brümmendorf; Fabian Beier
Journal:  Clin Case Rep       Date:  2022-05-05

3.  Acute neurotoxicity following vincristine due to Charcot-Marie-Tooth disease in a young child with medulloblastoma.

Authors:  Trisha Kissoon; Sridharan Gururangan; John Sladky
Journal:  Neurooncol Pract       Date:  2019-03-18

4.  Comparison of Myelin-Associated Glycoprotein With Vincristine for Facial Nerve Inhibition After Bilateral Axotomy in a Transgenic Thy1-Gfp Rat Model.

Authors:  S Ahmed Ali; John E Hanks; Aaron W Stebbins; Samantha T Cohen; Daniel A Hunter; Alison K Snyder-Warwick; Susan E Mackinnon; Robbi A Kupfer; Norman D Hogikyan; Eva L Feldman; Michael J Brenner
Journal:  JAMA Facial Plast Surg       Date:  2019-09-01       Impact factor: 4.611

Review 5.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

6.  Unmasking a Case of Asymptomatic Charcot-Marie-Tooth Disease (CMT1A) With Vincristine.

Authors:  Roopam Jariwal; Basel Shoua; Katayoun Sabetian; Piruthiviraj Natarajan; Everardo Cobos
Journal:  J Investig Med High Impact Case Rep       Date:  2018-02-26

7.  A Search for Undiagnosed Charcot-Marie-Tooth Disease Among Patients Registered with Unspecified Polyneuropathy in the Danish National Patient Registry.

Authors:  Signe Vaeth; Henning Andersen; Rikke Christensen; Uffe Birk Jensen
Journal:  Clin Epidemiol       Date:  2021-02-16       Impact factor: 4.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.